Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04818177 · ClinicalTrials.gov registry record

Immunoglobulin G Therapy Dose Optimization

A clinical trial of Obesity and Immune Deficiency, sponsored by Rutgers, The State University of New Jersey.

Completed
Registry status
40
Enrollment target
1
Study location

NCT04818177 is a study of Obesity and Immune Deficiency that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 40 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04818177, a study of Obesity and Immune Deficiency, has completed, sponsored by Rutgers, The State University of New Jersey.

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese patients. There is an ongoing debate regarding the most appropriate dosing of IgG formulations in obese patients. Obesity poses significant health risks; and evidence supporting dosing strategies of IgG in obese patients is inadequate. Some of the adverse reactions have been attributed to a relative overdosing in these patients, due to a limited distribution of IgG into fat tissue.

Interventions

  • DRUG Institutional standard intravenous immune globulin treatment

Study Locations (1)

New Jersey

  • Robert Wood Johnson University Hospital Somerset - Somerville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-04-01
Est. Completion 2025-08-01

What the Registry Record Tells You About NCT04818177

The ClinicalTrials.gov registry entry for NCT04818177 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Institutional standard intravenous immune globulin treatment is the first listed.

NCT04818177 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT04818177 about?

NCT04818177 is a clinical study titled "Immunoglobulin G Therapy Dose Optimization". The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese patients. There is an ongoing debate regarding the most appropriate dosing of IgG formulations in obese patients. ...

What is the current status of trial NCT04818177?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2021-04-01. Estimated completion is 2025-08-01.

What conditions does trial NCT04818177 study?

This clinical trial studies the following conditions: Obesity, Immune Deficiency.

What interventions are being tested in trial NCT04818177?

The interventions under investigation include: Institutional standard intravenous immune globulin treatment (DRUG).

Who is sponsoring clinical trial NCT04818177?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04818177 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.